These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 2025243)
1. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Veronese ME; Mackenzie PI; Doecke CJ; McManus ME; Miners JO; Birkett DJ Biochem Biophys Res Commun; 1991 Mar; 175(3):1112-8. PubMed ID: 2025243 [TBL] [Abstract][Full Text] [Related]
2. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Doecke CJ; Veronese ME; Pond SM; Miners JO; Birkett DJ; Sansom LN; McManus ME Br J Clin Pharmacol; 1991 Feb; 31(2):125-30. PubMed ID: 2049228 [TBL] [Abstract][Full Text] [Related]
3. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Veronese ME; Doecke CJ; Mackenzie PI; McManus ME; Miners JO; Rees DL; Gasser R; Meyer UA; Birkett DJ Biochem J; 1993 Jan; 289 ( Pt 2)(Pt 2):533-8. PubMed ID: 8424795 [TBL] [Abstract][Full Text] [Related]
4. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Yamazaki H; Inoue K; Shimada T Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436 [TBL] [Abstract][Full Text] [Related]
5. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Brian WR; Srivastava PK; Umbenhauer DR; Lloyd RS; Guengerich FP Biochemistry; 1989 Jun; 28(12):4993-9. PubMed ID: 2669966 [TBL] [Abstract][Full Text] [Related]
6. Differential inhibitory effects of phenytoin, diclofenac, phenylbutazone and a series of sulfonamides on hepatic cytochrome P4502C activity in vitro, and correlation with some molecular descriptors in the dwarf goat (Caprus hircus aegagrus). Zweers-Zeilmaker WM; Horbach GJ; Witkamp RF Xenobiotica; 1997 Aug; 27(8):769-80. PubMed ID: 9293615 [TBL] [Abstract][Full Text] [Related]
7. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Thijssen HH; Flinois JP; Beaune PH Drug Metab Dispos; 2000 Nov; 28(11):1284-90. PubMed ID: 11038154 [TBL] [Abstract][Full Text] [Related]
8. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Eagling VA; Tjia JF; Back DJ Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822 [TBL] [Abstract][Full Text] [Related]
9. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. Miners JO; Rees DL; Valente L; Veronese ME; Birkett DJ J Pharmacol Exp Ther; 1995 Mar; 272(3):1076-81. PubMed ID: 7891318 [TBL] [Abstract][Full Text] [Related]
10. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Lasker JM; Wester MR; Aramsombatdee E; Raucy JL Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596 [TBL] [Abstract][Full Text] [Related]
11. Cloning of a cDNA encoding a novel marmoset CYP2C enzyme, expression in yeast cells and characterization of its enzymatic functions. Narimatsu S; Torigoe F; Tsuneto Y; Saito K; Hanioka N; Masuda K; Katsu T; Yamamoto S; Yamano S; Baba T; Miyata A Biochem Pharmacol; 2006 Dec; 72(12):1738-48. PubMed ID: 17010942 [TBL] [Abstract][Full Text] [Related]
12. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2. Yoshimoto K; Echizen H; Chiba K; Tani M; Ishizaki T Br J Clin Pharmacol; 1995 Apr; 39(4):421-31. PubMed ID: 7640150 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of tolbutamide 4-methylhydroxylation by a series of non-steroidal anti-inflammatory drugs in V79-NH cells expressing human cytochrome P4502C10. Kappers WA; Groene EM; Kleij LA; Witkamp RF; Zweers-Zeilmaker WM; Feron VJ; Horbach GJ Xenobiotica; 1996 Dec; 26(12):1231-9. PubMed ID: 9004453 [TBL] [Abstract][Full Text] [Related]
14. Roles of human liver cytochrome P4502C and 3A enzymes in the 3-hydroxylation of benzo(a)pyrene. Yun CH; Shimada T; Guengerich FP Cancer Res; 1992 Apr; 52(7):1868-74. PubMed ID: 1551116 [TBL] [Abstract][Full Text] [Related]
15. [O-methyl 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Rodrigues AD; Kukulka MJ; Roberts EM; Ouellet D; Rodgers TR Drug Metab Dispos; 1996 Jan; 24(1):126-36. PubMed ID: 8825200 [TBL] [Abstract][Full Text] [Related]
17. Tolbutamide hydroxylation by human, rabbit and rat liver microsomes and by purified forms of cytochrome P-450. Veronese ME; McManus ME; Laupattarakasem P; Miners JO; Birkett DJ Drug Metab Dispos; 1990; 18(3):356-61. PubMed ID: 1974199 [TBL] [Abstract][Full Text] [Related]
18. Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. Zhou S; Paxton JW; Tingle MD; Kestell P Drug Metab Dispos; 2000 Dec; 28(12):1449-56. PubMed ID: 11095582 [TBL] [Abstract][Full Text] [Related]
19. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Miners JO; Smith KJ; Robson RA; McManus ME; Veronese ME; Birkett DJ Biochem Pharmacol; 1988 Mar; 37(6):1137-44. PubMed ID: 3355588 [TBL] [Abstract][Full Text] [Related]
20. Allelic and functional variability of cytochrome P4502C9. Bhasker CR; Miners JO; Coulter S; Birkett DJ Pharmacogenetics; 1997 Feb; 7(1):51-8. PubMed ID: 9110362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]